Sun Pharma Secures AAA Rating for Rs 15,000 Crore Debt Plan

Rating agencies CRISIL and ICRA have assigned 'AAA/Stable' ratings to Sun Pharma's proposed Rs 15,000 crore non-convertible debenture (NCD) programme.

Reader Takeaway: Strong credit profile supports debt plans, though acquisition leverage and US regulatory compliance remain key areas for monitoring.

What just happened

Sun Pharmaceutical Industries has received top-tier credit ratings from both CRISIL and ICRA for its new debt issuance. The agencies have also reaffirmed the company's existing long-term and short-term credit ratings at 'AAA' and 'A1+' respectively. These ratings indicate the highest degree of safety regarding the timely servicing of financial obligations.

Why this matters

The 'AAA' rating provides Sun Pharma with access to capital at competitive interest rates. The assessment comes as the company prepares for the acquisition of Organon & Co., valued at $11.75 billion. While the acquisition is expected to raise the company's net debt/EBITDA ratio to between 1.5x and 2.0x by FY2028, analysts expect Sun Pharma’s strong cash flow generation to facilitate steady deleveraging.

Business and Financial Context

Sun Pharma continues to hold a leadership position in the Indian formulations market, which accounts for approximately 33% of its revenue. Its global footprint remains strong, with innovative products now contributing roughly 22% of total revenue. Recent launches, including Leqselvi and UNLOXYCT, underscore the firm’s focus on high-value products to offset pricing pressure in the US generic market.

Risks to watch

Investors should monitor the integration of the Organon & Co. business to ensure projected synergies are realized. Additionally, the company faces ongoing regulatory scrutiny at certain manufacturing facilities. Sustained compliance is critical for maintaining market access. External factors, such as shifts in US drug pricing policies or potential tariff changes, also remain on the radar for rating agencies.

What to track next

The market will look for updates on the closure of the Organon acquisition and progress in reducing leverage post-deal. Compliance reports regarding US-based manufacturing sites will also be vital to ensuring no disruption to supply chains.